Opening remarks
During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.
MeeW A/S (“MeeW” or the “Company”) hereby announces that Spotlight Stock Market has given its approval for listing of the Company’s securities on Spotlight Stock Market. The approval is given under the condition that MeeW raises the minimum limit and obtains a sufficient ownership dispersion in its upcoming initial public offering of maximum approx. DKK 18.5 million (the “IPO” or the “Offer”). MeeW hereby also publishes the memorandum relating to the Offer. The subscription period in the Offer runs from 21 February 2023 until and including 7 March 2023. MeeW has received pre-subscription commitments amounting to approx. DKK 9.3 million and guarantee commitments amount to approx. DKK 5.55 million, in total approx. DKK 14.85 million corresponding to approx. 80 percent of the Offer. The memorandum is available at MeeW’s (www.meew.dk), SeaHouse Capital ApS’s (www.seahousecapital.dk), Nordic Issuing AB’s (www.nordic-issuing.se), and Spotlight Stock Market’s (www.sp
Today s Morning View - Covid Lockdowns in China outweigh positive economic data proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.